126 related articles for article (PubMed ID: 38218180)
1. Structural insight into CD93 recognition by IGFBP7.
Xu Y; Sun Y; Zhu Y; Song G
Structure; 2024 Mar; 32(3):282-291.e4. PubMed ID: 38218180
[TBL] [Abstract][Full Text] [Related]
2. Structural insight into CD93 recognition by IGFBP7.
Xu Y; Sun Y; Zhu Y; Song G
bioRxiv; 2023 Jun; ():. PubMed ID: 37333140
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy.
Sun Y; Chen W; Torphy RJ; Yao S; Zhu G; Lin R; Lugano R; Miller EN; Fujiwara Y; Bian L; Zheng L; Anand S; Gao F; Zhang W; Ferrara SE; Goodspeed AE; Dimberg A; Wang XJ; Edil BH; Barnett CC; Schulick RD; Chen L; Zhu Y
Sci Transl Med; 2021 Jul; 13(604):. PubMed ID: 34321321
[TBL] [Abstract][Full Text] [Related]
4. CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.
Lugano R; Vemuri K; Yu D; Bergqvist M; Smits A; Essand M; Johansson S; Dejana E; Dimberg A
J Clin Invest; 2018 Aug; 128(8):3280-3297. PubMed ID: 29763414
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization.
Li Y; Fu L; Wu B; Guo X; Shi Y; Lv C; Yu Y; Zhang Y; Liang Z; Zhong C; Han S; Xu F; Tian Y
Cancer Cell Int; 2023 Sep; 23(1):189. PubMed ID: 37660019
[TBL] [Abstract][Full Text] [Related]
6. The small GTPase Rab5c is a key regulator of trafficking of the CD93/Multimerin-2/β1 integrin complex in endothelial cell adhesion and migration.
Barbera S; Nardi F; Elia I; Realini G; Lugano R; Santucci A; Tosi GM; Dimberg A; Galvagni F; Orlandini M
Cell Commun Signal; 2019 May; 17(1):55. PubMed ID: 31138217
[TBL] [Abstract][Full Text] [Related]
7. Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium.
Galvagni F; Nardi F; Spiga O; Trezza A; Tarticchio G; Pellicani R; Andreuzzi E; Caldi E; Toti P; Tosi GM; Santucci A; Iozzo RV; Mongiat M; Orlandini M
Matrix Biol; 2017 Dec; 64():112-127. PubMed ID: 28912033
[TBL] [Abstract][Full Text] [Related]
8. Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.
Langenkamp E; Zhang L; Lugano R; Huang H; Elhassan TE; Georganaki M; Bazzar W; Lööf J; Trendelenburg G; Essand M; Pontén F; Smits A; Dimberg A
Cancer Res; 2015 Nov; 75(21):4504-16. PubMed ID: 26363010
[TBL] [Abstract][Full Text] [Related]
9. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.
Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R
Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670
[TBL] [Abstract][Full Text] [Related]
10. CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration adhesion and migration.
Galvagni F; Nardi F; Maida M; Bernardini G; Vannuccini S; Petraglia F; Santucci A; Orlandini M
Oncotarget; 2016 Mar; 7(9):10090-103. PubMed ID: 26848865
[TBL] [Abstract][Full Text] [Related]
11. The Binding of CD93 to Multimerin-2 Promotes Choroidal Neovascularization.
Tosi GM; Neri G; Barbera S; Mundo L; Parolini B; Lazzi S; Lugano R; Poletto E; Leoncini L; Pertile G; Mongiat M; Dimberg A; Galvagni F; Orlandini M
Invest Ophthalmol Vis Sci; 2020 Jul; 61(8):30. PubMed ID: 32697305
[TBL] [Abstract][Full Text] [Related]
12. Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets.
Guo A; Zhang J; Tian Y; Peng Y; Luo P; Zhang J; Liu Z; Wu W; Zhang H; Cheng Q
Front Immunol; 2022; 13():907182. PubMed ID: 36389798
[TBL] [Abstract][Full Text] [Related]
13. CD93 a potential player in cytotrophoblast and endothelial cell migration.
Fantone S; Tossetta G; Di Simone N; Tersigni C; Scambia G; Marcheggiani F; Giannubilo SR; Marzioni D
Cell Tissue Res; 2022 Jan; 387(1):123-130. PubMed ID: 34674045
[TBL] [Abstract][Full Text] [Related]
14. CD93 interacts with the PDZ domain-containing adaptor protein GIPC: implications in the modulation of phagocytosis.
Bohlson SS; Zhang M; Ortiz CE; Tenner AJ
J Leukoc Biol; 2005 Jan; 77(1):80-9. PubMed ID: 15459234
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of CD93 promotes angiogenesis and tumor growth in nasopharyngeal carcinoma.
Bao L; Tang M; Zhang Q; You B; Shan Y; Shi S; Li L; Hu S; You Y
Biochem Biophys Res Commun; 2016 Aug; 476(4):467-474. PubMed ID: 27255994
[TBL] [Abstract][Full Text] [Related]
16. CD93 Signaling via Rho Proteins Drives Cytoskeletal Remodeling in Spreading Endothelial Cells.
Barbera S; Raucci L; Lugano R; Tosi GM; Dimberg A; Santucci A; Galvagni F; Orlandini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830297
[TBL] [Abstract][Full Text] [Related]
17. The epidermal growth factor-like domain of CD93 is a potent angiogenic factor.
Kao YC; Jiang SJ; Pan WA; Wang KC; Chen PK; Wei HJ; Chen WS; Chang BI; Shi GY; Wu HL
PLoS One; 2012; 7(12):e51647. PubMed ID: 23272129
[TBL] [Abstract][Full Text] [Related]
18. Modulated interaction of the ERM protein, moesin, with CD93.
Zhang M; Bohlson SS; Dy M; Tenner AJ
Immunology; 2005 May; 115(1):63-73. PubMed ID: 15819698
[TBL] [Abstract][Full Text] [Related]
19. CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma.
Bohlson SS; Silva R; Fonseca MI; Tenner AJ
J Immunol; 2005 Jul; 175(2):1239-47. PubMed ID: 16002728
[TBL] [Abstract][Full Text] [Related]
20. CD93 promotes acute myeloid leukemia development and is a potential therapeutic target.
Jia J; Liu B; Wang D; Wang X; Song L; Ren Y; Guo Z; Ma K; Cui C
Exp Cell Res; 2022 Nov; 420(2):113361. PubMed ID: 36152731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
